Pfizer picks WPP firms to handle cardiovascular products

NEW YORK: Pfizer has entrusted WPP, with Cohn & Wolfe at the helm, to handle global PR responsibilities for three leading products in its cardiovascular franchise, which includes Lipitor, the world?s best-selling drug.

NEW YORK: Pfizer has entrusted WPP, with Cohn & Wolfe at the helm, to handle global PR responsibilities for three leading products in its cardiovascular franchise, which includes Lipitor, the world?s best-selling drug.

The decision comes two months after Pfizer invited the world?s three largest marketing holding companies - WPP, IPG, and Omnicom - to each assemble their strongest PR teams to pitch for the business. Earlier this month, Omnicom dropped out of the race.

In addition to Lipitor, the account includes Norvasc, a treatment for hypertension and angina, and Caduet, a dual therapy of Lipitor and Norvasc currently awaiting FDA approval.

Check PRWeek.com and the February 2 issue of PRWeek magazine for further updates on this story

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.